Agilum Releases Additional RWD Survival Rate Analytics for HCQ or CQ and Acetazolamide

Updated June 30, 2020

Agilum first began publishing RWD on COVID-19 hospital admissions on April 7, 2020. The real-world data (RWD) were refreshed daily and showed notable differences in survival rates and ALOS across recognized drug treatment regimens. This analysis was presumptive in nature and sought to produce RWD in near-real-time to advance the care and treatment of these patients.

As the rate of COVID-19 hospital admissions slows, Agilum will sunset the daily reports and continue to support our customers by providing real-world data and real-world evidence to help improve patient outcomes. 



By: William D. Kirsh, DO, MPH, CMIO, Agilum Healthcare Intelligence, Inc. and
Travis J. Leonardi, RPh, C.P., CEO of Agilum Healthcare Intelligence, Inc.


Through its Comparative Rapid Cycle Analytics™ (CRCA™) solution, Agilum Healthcare Intelligence seeks to leverage its comprehensive, longitudinal patient database to deliver updates on current and new treatment regimens – providing greater transparency into the resulting outcomes for various cohorts of COVID-19 patients. This data supports more detailed observations into the survival rate by drug treatment regimens for COVID-19 patients with and without comorbid conditions (determined by a pulmonary and/or cardiac diagnosis within the past 12 calendar months). Specifically, this information is grouped into a known COVID-19 regimen: hydroxychloroquine or chloroquine and acetazolamide (“HCQ or CQ and Acetazolamide”). Observations are based on:

  • Real-world data (RWD) from inpatient care including drug dispensation data
  • A representative sampling of patients in hospitals across the United States
  • Dynamic, real-time, continuously updated information

With the rapidly evolving incidence of COVID-19, this report will be refreshed regularly to show near real-time trends of patient outcomes based on specific drug treatment regimens.

COVID-19 Nationwide Real-World Data (RWD) Inpatient Drug Regimen Analysis:
Drug Protocols of Hydroxychloroquine or Chloroquine and Acetazolamide


Clinicians have observed and reported that chest x-ray and CT scan lung imaging of COVID-19 patients shows patterns consistent with High Altitude Pulmonary Edema (HAPE). Acetazolamide is a common treatment for this condition, and as such, we have witnessed a measurable increase in the use of this medication in combination with hydroxychloroquine or chloroquine in the treatment of COVID-19 patients.

In the continued interest of producing information to support and advance the care of these patients, we seek to provide an individualized look at the real-world data (RWD) surrounding this drug regimen.


By leveraging Agilum’s Comparative Rapid Cycle Analytics™ (CRCA™) platform, Agilum has written protocols to analyze real-world data (RWD) from the inpatient care setting taking place in hospitals nationwide treating patients with COVID-19. The data tables contained herein were constructed using RWD to create an analytical approach, as opposed to a clinical study such as a randomized control trial. In doing so, we seek to advance the rapidly evolving body of knowledge pertaining to the care and treatment of patients with COVID-19 using near real-time longitudinal patient data. The data will be updated and republished continuously as available.


  • Examined inpatient dispensations of select drugs from March 1, 2020 through June 15, 2020, from hospitals nationwide. Leveraged a current, near-real-time data stream to ensure timeliness and accuracy.
  • Grouped drugs into a specific known COVID-19 regimen: hydroxychloroquine or chloroquine and acetazolamide (“HCQ or CQ and Acetazolamide”).
  • Analyzed patients by age and gender on each regimen for outcomes associated with survival rates.
  • Analysis factors comorbid conditions related to cardiac and pulmonary diseases, using ICD-10 CM diagnosis codes corresponding to the respective clinical classes as defined by the Agency for Healthcare Research and Quality (AHRQ).
  • All patients in this analysis were hospitalized and treated with the drug regimens listed herein. The analysis does not contain patients who were treated outside of these drug regimens.




  • Based on observation of real-world data analytics, not a clinical study or trial.
  • This information is for observational purposes only and is not a recommendation, endorsement or advice as to any medical or therapeutic treatment option. We advise readers to consult with medical professionals and public health authorities regarding treatment of any COVID-19 infection.
  • The information is subject to change without notice. The information is solely based on data received.
  • All product names and trademarks are the property of their respective owners.

To download the final PDF of this analysis, simply fill out the form below. For more information about this analysis or Agilum Healthcare Intelligence solutions, please call 877.AGLMHCI (245.6424).